Pages that link to "Q91940474"

The following pages link to Mark Larché (Q91940474):

Displaying 47 items.

• T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity (Q24805470) (← links)
• Immunological mechanisms of allergen-specific immunotherapy (Q28265326) (← links)
• Proceedings of the Canadian society of allergy and clinical immunology annual scientific meeting 2015 (Q28553841) (← links)
• Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (Q30371972) (← links)
• Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012-2015. (Q31161641) (← links)
• The effect of rituximab on vaccine responses in patients with immune thrombocytopenia (Q33409067) (← links)
• Restricted usage of T-cell receptor V alpha sequence and variable-joining pairs after normal T-cell development and bone marrow transplantation (Q34344984) (← links)
• The potential of peptide immunotherapy in allergy and asthma (Q34561901) (← links)
• The role of T lymphocytes in the pathogenesis of asthma (Q35087292) (← links)
• Peptide-based vaccines in the treatment of specific allergy (Q35560582) (← links)
• Allergen immunotherapy with cat allergen peptides (Q35685198) (← links)
• The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses (Q35915934) (← links)
• Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects (Q36225936) (← links)
• Peptide-based immunotherapy: a novel strategy for allergic disease (Q36350581) (← links)
• Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression (Q37273245) (← links)
• Proliferation of Circulating T-Lymphocytes (Q37839861) (← links)
• T Cell Epitope-Based Allergy Vaccines (Q37874994) (← links)
• An Update on Lymphocyte Subtypes in Asthma and Airway Disease (Q39000453) (← links)
• Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. (Q39796254) (← links)
• Erratum to: Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement (Q42331374) (← links)
• Allergen immunotherapy on the way to product-based evaluation-a WAO statement (Q43249691) (← links)
• Environmental influence on T cell receptor alpha gene rearrangement and expression in vitro (Q43425500) (← links)
• Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides (Q44590578) (← links)
• Canadian Society of Allergy and Clinical Immunology annual scientific meeting 2016. (Q45790663) (← links)
• AllerGen’s 8th research conference. (Q45825483) (← links)
• Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes. (Q46028664) (← links)
• Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. (Q46720701) (← links)
• Immunotherapy – 2067. FEL d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study. (Q47110312) (← links)
• Investigating Immune Gene Signatures in Peripheral Blood from Subjects with Allergic Rhinitis Undergoing Nasal Allergen Challenge. (Q47739919) (← links)
• Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis. (Q47965294) (← links)
• Diversity of T-cell receptor alpha gene transcripts in the newborn and adult periphery (Q48193789) (← links)
• Developmental T cell receptor gene rearrangements: relatedness of the alpha/beta and gamma/delta T cell precursor. (Q52236126) (← links)
• Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. (Q52714111) (← links)
• The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy. (Q55322428) (← links)
• Mechanisims of asthma and allergic disease – 1085. Safety and tolerability of escalating doses of house dust mite peptide antigen desensitisation. (Q55619826) (← links)
• Immunotherapy – 2080. Fel d 1 derived peptide antigen desensitization results in a persistent treatment effect on symptoms of cat allergy 1 year after 4 doses (Q59304123) (← links)
• Environmental and allele-specific influences on T cell receptor gene rearrangement: skewed alpha, delta, and gamma gene rearrangement patterns in chimeric mice (Q68266211) (← links)
• Fetal thymocyte potential for T cell receptor V gamma 3-J gamma 1 junctional modification (Q70457273) (← links)
• T‐cell responses to house dust mites: bad news for immunotherapy? (Q73683901) (← links)
• Peptide therapy and asthma (Q80179009) (← links)
• Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy (Q89115633) (← links)
• Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen (Q90311884) (← links)
• Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy (Q91940480) (← links)
• Increased cytotoxic potential of CD8+ T cells in immune thrombocytopenia (Q92076122) (← links)
• Legends of allergy/immunology: A. Barry Kay (Q92695283) (← links)
• Immunological changes in peripheral blood following nasal allergen challenge in subjects with allergic rhinitis pre- and post-peptide immunotherapy: an open-label clinical study (Q104475424) (← links)
• Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections (Q120671423) (← links)